H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Entrada Therapeutics to $18 from $20 and keeps a Buy rating on the shares. The company announced positive preliminary data from its Phase 1 clinical trial, ENTR-601-44-101, the analyst tells investors in a research note. The firm cites equity financing dilution for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics Announces $100 Million Registered Direct Offering
- Entrada Therapeutics’ Promising Phase 1 DMD Drug Trial Results
- Entrada Therapeutics reports ‘positive’ data from Phase 1 ENTR-601-44-101 trial
- Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
- Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference